European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer
GlobeNewswire
*European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive..